CoChat

Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease

Polyzos, Stergios A., Kountouras, Jannis, Zavos, Christos, Deretzi, Georgia · 2012 · Journal of Clinical Gastroenterology
Cited by 152

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Nonalcoholic fatty liver disease (NAFLD) has emerged as a significant public health problem. Besides the liver, NAFLD is also associated with increased cardiovascular and overall morbidity and mortality. NAFLD warrants intensive research, because no treatment has been established as yet. This may be partly attributed to the fact that the majority of the relative clinical trials have a monotherapeutic direction. However, the multifactorial pathogenesis of NAFLD may probably direct clinical trials to a combined therapeutic approach. The aim of this review is to provide a description of the multifactorial pathogenesis of NAFLD and type II diabetes mellitus-NAFLD interplay, and to summarize the therapeutic trials focusing on the combined NAFLD treatment, providing a link between the multiple-hit pathogenesis and the multimodal treatment of NAFLD patients. A diabetes-like therapeutic approach for NAFLD is finally proposed.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/mcg.0b013e31824587e0

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Research works printed but not linked: 64

  1. Sanyal, 2011, NASH: a global health problem., Hepatol Res, 41, 670, 10.1111/j.1872-034X.2011.00824.x · DOI · Paper page
  2. Vernon, 2011, Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults., Aliment Pharmacol Ther, 34, 274, 10.1111/j.1365-2036.2011.04724.x · DOI · Paper page
  3. Hamaguchi, 2005, The metabolic syndrome as a predictor of nonalcoholic fatty liver disease., Ann Intern Med, 143, 722, 10.7326/0003-4819-143-10-200511150-00009 · DOI · Paper page
  4. Whalley, 2007, Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs., Clin Med, 7, 119, 10.7861/clinmedicine.7-2-119 · DOI · Paper page
  5. Suzuki, 2005, Chronological development of elevated aminotransferases in a nonalcoholic population., Hepatology, 41, 64, 10.1002/hep.20543 · DOI · Paper page
  6. Williams, 2011, Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study., Gastroenterology, 140, 124, 10.1053/j.gastro.2010.09.038 · DOI · Paper page
  7. Chitturi, 2011, Nonalcoholic fatty liver in Asia: firmly entrenched and rapidly gaining ground., J Gastroenterol Hepatol, 26, 163, 10.1111/j.1440-1746.2010.06548.x · DOI · Paper page
  8. Polyzos, 2009, Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines., Curr Mol Med, 72, 299, 10.2174/156652409787847191 · DOI · Paper page
  9. Musso, 2011, Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity., Ann Med, 43, 617, 10.3109/07853890.2010.518623 · DOI · Paper page
  10. Younossi, 2011, Pathologic criteria for nonalcoholic steatohepatitis: interprotocol agreement and ability to predict liver-related mortality., Hepatology, 53, 1874, 10.1002/hep.24268 · DOI · Paper page
  11. Calori, 2011, Fatty liver index (FLI) and mortality: the cremona study at the 15(th) year of follow up., Hepatology, 54, 145, 10.1002/hep.24356 · DOI · Paper page
  12. Ertle, 2011, Non-alcoholic fatty liver disease progresses to hepatocellular carcinoma in the absence of apparent cirrhosis., Int J Cancer, 128, 2436, 10.1002/ijc.25797 · DOI · Paper page
  13. Ong, 2008, Increased overall mortality and liver-related mortality in non-alcoholic fatty liver disease., J Hepatol, 49, 608, 10.1016/j.jhep.2008.06.018 · DOI · Paper page
  14. Polyzos, 2009, The multi-hit process and the antagonistic roles of tumor necrosis factor-alpha and adiponectin in nonalcoholic fatty liver disease., Hippokratia, 13, 127
  15. Krawczyk, 2010, Nonalcoholic fatty liver disease., Best Pract Res Clin Gastroenterol, 24, 695, 10.1016/j.bpg.2010.08.005 · DOI · Paper page
  16. Daly, 2011, Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease., Expert Rev Gastroenterol Hepatol, 5, 253, 10.1586/egh.11.18 · DOI
  17. Chalasani, 2010, Genome-wide association study identifies variants associated with histologic features of nonalcoholic fatty liver disease., Gastroenterology, 139, 1567, 10.1053/j.gastro.2010.07.057 · DOI · Paper page
  18. Sookoian, 2011, Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease., Hepatology, 53, 1883, 10.1002/hep.24283 · DOI · Paper page
  19. Lonardo, 2011, Perspectives on cellular dysfunction in nonalcoholic steatohepatitis: a case of multiorganelle failure Proceedings of a virtual workshop on nonalcoholic steatohepatitis., Expert Rev Gastroenterol Hepatol, 5, 135, 10.1586/egh.11.24 · doi:10.1586/egh.11.24
  20. Tilg, 2010, Update on nonalcoholic fatty liver disease: genes involved in nonalcoholic fatty liver disease and associated inflammation., Curr Opin Clin Nutr Metab Care, 13, 391, 10.1097/MCO.0b013e32833a87cc · DOI
  21. Zhan, 2010, Roles of liver innate immune cells in nonalcoholic fatty liver disease., World J Gastroenterol, 16, 4652, 10.3748/wjg.v16.i37.4652 · DOI · Paper page
  22. Ratziu, 2010, A position statement on NAFLDNASH based on the EASL 2009 special conference., J Hepatol, 53, 372, 10.1016/j.jhep.2010.04.008 · DOI · Paper page
  23. Nseir, 2011, Mechanisms linking nonalcoholic fatty liver disease with coronary artery disease., Dig Dis Sci, 56, 3439, 10.1007/s10620-011-1767-y · DOI
  24. Valenti, 2010, Homozygosity for the patatin-like phospholipase-3adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease., Hepatology, 51, 1209, 10.1002/hep.23622 · DOI · Paper page
  25. Valenti, 2011, Patatin-like phospholipase domain-containing 3 I148M polymorphism, steatosis, and liver damage in chronic hepatitis C., Hepatology, 53, 791, 10.1002/hep.24123 · DOI · Paper page
  26. Greenberg, 2011, The role of lipid droplets in metabolic disease in rodents and humans., J Clin Invest, 121, 2102, 10.1172/JCI46069 · DOI · Paper page
  27. Samuel, 2011, Fructose induced lipogenesis: from sugar to fat to insulin resistance., Trends Endocrinol Metab, 22, 60, 10.1016/j.tem.2010.10.003 · DOI · Paper page
  28. Lombardi, 1968, Choline-deficiency fatty liver: impaired release of hepatic triglycerides., J Lipid Res, 9, 437, 10.1016/S0022-2275(20)42721-X · DOI
  29. Koek, 2011, The role of oxidative stress in non-alcoholic steatohepatitis., Clin Chim Acta, 412, 1297, 10.1016/j.cca.2011.04.013 · DOI · Paper page
  30. Dara, 2011, The contribution of endoplasmic reticulum stress to liver diseases., Hepatology, 53, 1752, 10.1002/hep.24279 · DOI · Paper page
  31. Serviddio, 2011, Mitochondrial dysfunction in nonalcoholic steatohepatitis., Expert Rev Gastroenterol Hepatol, 5, 233, 10.1586/egh.11.11 · DOI
  32. Targher, 2007, Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients., Diabetes Care, 30, 1212, 10.2337/dc06-2247 · DOI · Paper page
  33. Prashanth, 2009, Prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus., J Assoc Physicians India, 57, 205
  34. Williamson, 2011, Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study., Diabetes Care, 34, 1139, 10.2337/dc10-2229 · DOI · Paper page
  35. Leite, 2011, Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors., Liver Int, 31, 700, 10.1111/j.1478-3231.2011.02482.x · DOI · Paper page
  36. Smith, 2011, Nonalcoholic fatty liver disease and diabetes mellitus: pathogenesis and treatment., Nat Rev Endocrinol, 7, 456, 10.1038/nrendo.2011.72 · DOI · Paper page
  37. Manchanayake, 2011, Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease., J Gastroenterol Hepatol, 26, 510, 10.1111/j.1440-1746.2010.06528.x · DOI · Paper page
  38. Carvalho, 2011, The Finnish Diabetes Risk Score (FINDRISC) as a screening tool for hepatic steatosis., Ann Med, 43, 487, 10.3109/07853890.2011.554428 · DOI
  39. Musso, 2010, A meta-analysis of randomized trials for the treatment of nonalcoholic fatty liver disease., Hepatology, 52, 79, 10.1002/hep.23623 · DOI · Paper page
  40. Dowman, 2011, Current therapeutic strategies in non-alcoholic fatty liver disease., Diabetes Obes Metab, 13, 692, 10.1111/j.1463-1326.2011.01403.x · DOI · Paper page
  41. Kaser, 2010, Pharmacological and non-pharmacological treatment of non-alcoholic fatty liver disease., Int J Clin Pract, 64, 968, 10.1111/j.1742-1241.2009.02327.x · DOI
  42. Wang, 2011, The PNPLA3 I148M polymorphism is associated with insulin resistance and nonalcoholic fatty liver disease in a normoglycaemic population., Liver Int, 31, 1326, 10.1111/j.1478-3231.2011.02526.x · DOI
  43. Petit, 2011, PNPLA3 polymorphism influences liver fibrosis in unselected patients with type 2 diabetes., Liver Int, 31, 1332, 10.1111/j.1478-3231.2011.02566.x · DOI
  44. Cox, 2011, Association of PNPLA3 SNP rs738409 with liver density in African Americans with type 2 diabetes mellitus., Diabetes Metab, 37, 452, 10.1016/j.diabet.2011.05.001 · doi:10.1016/j.diabet.2011.05.001
  45. Sanyal, 2011, Endpoints and clinical trial design for nonalcoholic steatohepatitis., Hepatology, 54, 344, 10.1002/hep.24376 · DOI · Paper page
  46. Loria, 2010, Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the Italian Association for the Study of the Liver (AISF) Expert Committee., Dig Liver Dis, 42, 272, 10.1016/j.dld.2010.01.021 · DOI · Paper page
  47. Lutchman, 2007, The effects of discontinuing pioglitazone in patients with nonalcoholic steatohepatitis., Hepatology, 46, 424, 10.1002/hep.21661 · DOI · Paper page
  48. Nissen, 2010, Rosiglitazone revisited: an updated meta-analysis of risk for myocardial infarction and cardiovascular mortality., Arch Intern Med, 170, 1191, 10.1001/archinternmed.2010.207 · DOI · Paper page
  49. Harrison, 2003, Vitamin E and vitamin C treatment improves fibrosis in patients with nonalcoholic steatohepatitis., Am J Gastroenterol, 98, 2485, 10.1111/j.1572-0241.2003.08699.x · doi:10.1111/j.1572-0241.2003.08699.x · Paper page
  50. Athyros, 2006, Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study., Curr Med Res Opin, 22, 873, 10.1185/030079906X104696 · DOI · Paper page
  51. Filippatos, 2010, Combination drug treatment in patients with non-alcoholic fatty liver disease., World J Hepatol, 2, 139, 10.4254/wjh.v2.i4.139 · DOI
  52. Voican, 2011, Insulin resistance and oxidative stress: two therapeutic targets in non-alcoholic steatohepatitis., J Hepatol, 54, 388, 10.1016/j.jhep.2010.07.054 · DOI
  53. Abel, 2009, Safety and efficacy of combined ezetimibesimvastatin treatment and simvastatin monotherapy in patients with non-alcoholic fatty liver disease., Med Sci Monit, 15, 6
  54. Dufour, 2006, Randomized placebo-controlled trial of ursodeoxycholic acid with vitamin E in nonalcoholic steatohepatitis., Clin Gastroenterol Hepatol, 4, 1537, 10.1016/j.cgh.2006.09.025 · DOI · Paper page
  55. Balmer, 2009, Effects of ursodeoxycholic acid in combination with vitamin E on adipokines and apoptosis in patients with nonalcoholic steatohepatitis., Liver Int, 29, 1184, 10.1111/j.1478-3231.2009.02037.x · DOI · Paper page
  56. Ersoz, 2005, Management of fatty liver disease with vitamin E and C compared to ursodeoxycholic acid treatment., Turk J Gastroenterol, 16, 124
  57. Foster, 2011, Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial., Am J Gastroenterol, 106, 71, 10.1038/ajg.2010.299 · DOI · Paper page
  58. Loguercio, 2007, The effect of a silybin-vitamin E-phospholipid complex on nonalcoholic fatty liver disease: a pilot study., Dig Dis Sci, 52, 2387, 10.1007/s10620-006-9703-2 · DOI
  59. Nobili, 2006, Effect of vitamin E on aminotransferase levels and insulin resistance in children with non-alcoholic fatty liver disease., Aliment Pharmacol Ther, 24, 1553, 10.1111/j.1365-2036.2006.03161.x · DOI · Paper page
  60. Nobili, 2008, Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: a randomized, controlled trial., Hepatology, 48, 119, 10.1002/hep.22336 · DOI · Paper page
  61. Omer, 2010, Efficacy of insulin-sensitizing agents in nonalcoholic fatty liver disease., Eur J Gastroenterol Hepatol, 22, 18, 10.1097/MEG.0b013e32832e2baf · DOI · Paper page
  62. Polyzos, 2011, Effect of spironolactone and vitamin E on serum metabolic parameters and insulin resistance in patients with nonalcoholic fatty liver disease., J Renin Angiotensin Aldosterone Syst, 12, 498, 10.1177/1470320311402110 · DOI
  63. Sanyal, 2004, A pilot study of vitamin E versus vitamin E and pioglitazone for the treatment of nonalcoholic steatohepatitis., Clin Gastroenterol Hepatol, 2, 1107, 10.1016/S1542-3565(04)00457-4 · DOI · Paper page
  64. Yokohama, 2004, Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis., Hepatology, 40, 1222, 10.1002/hep.20420 · DOI · Paper page

Cited by

See all 152

Metadata

Authors
Polyzos, S. A., Kountouras, J., Zavos, C., & Deretzi, G.
Venue
Journal of Clinical Gastroenterology
Published
2012-04
Volume
46
Issue
4
Pages
272-284
ISSN
0192-0790 (ISSN-L)
OpenAlex
W2047189101
Cited by
152
References
14
FWCI
9.05
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease. https://app.cochat.ai/papers/10.1097/mcg.0b013e31824587e0
The paper
Polyzos, S. A., Kountouras, J., Zavos, C., & Deretzi, G. (2012). Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-hit Disease. Journal of Clinical Gastroenterology. https://doi.org/10.1097/mcg.0b013e31824587e0

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.